Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Gross Margin (2016 - 2025)

Amphastar Pharmaceuticals has reported Gross Margin over the past 13 years, most recently at 46.79% for Q4 2025.

  • Quarterly results put Gross Margin at 46.79% for Q4 2025, up 33.0% from a year ago — trailing twelve months through Dec 2025 was 49.46% (down 162.0% YoY), and the annual figure for FY2025 was 49.46%, down 162.0%.
  • Gross Margin for Q4 2025 was 46.79% at Amphastar Pharmaceuticals, down from 51.42% in the prior quarter.
  • Over the last five years, Gross Margin for AMPH hit a ceiling of 60.04% in Q3 2023 and a floor of 43.63% in Q1 2021.
  • Median Gross Margin over the past 5 years was 49.96% (2025), compared with a mean of 50.02%.
  • Biggest five-year swings in Gross Margin: soared 1133bps in 2023 and later crashed -753bps in 2024.
  • Amphastar Pharmaceuticals' Gross Margin stood at 46.52% in 2021, then grew by 13bps to 52.71% in 2022, then increased by 2bps to 53.98% in 2023, then dropped by -14bps to 46.45% in 2024, then grew by 1bps to 46.79% in 2025.
  • The last three reported values for Gross Margin were 46.79% (Q4 2025), 51.42% (Q3 2025), and 49.59% (Q2 2025) per Business Quant data.